Cargando...
Novel formulation of cytarabine and daunorubicin: A new hope in AML treatment
Acute myeloid leukemia (AML) treatment has always been a challenge to the treating physician. Continuous efforts are being made to improve treatment outcomes in AML. CPX-351 is a pharmacologic advancement in this direction. It is a liposomal fixed drug combination of cytarabine and daunorubicin. Ear...
Gardado en:
| Publicado en: | South Asian J Cancer |
|---|---|
| Autor Principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Medknow Publications & Media Pvt Ltd
2015
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4382783/ https://ncbi.nlm.nih.gov/pubmed/25839020 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/2278-330X.149950 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|